Donate

infliximab

Home»Posts tagged with»infliximab

REACT clinical trial of accelerated treatment for Crohn’s disease

The final results from an international clinical trial involving nearly 2,000 patients with Crohn’s disease support the use of a new management strategy referred to as accelerated step-care as a best practice for the care of active Crohn’s disease. The REACT (Randomized Evaluation of an Algorithm for Crohn’s Treatment) study, led by Robarts Clinical Trials […]

Assessment of the Social Cost of Crohn’s Disease

Assessment of the Social Cost of Crohn’s Disease, Participants with Crohn’s Disease for at least 6 months, who have a Crohn’s Disease Activity Index (CDAI) score >= 150, seen at one of 25 gastroenterology centers spread across Italy. The CDAI score evaluates Crohn’s disease symptoms – a score of 150 or below indicates remission and […]

FDA Committee Recommends Approval of Vedolizumab

FDA Committee Recommends Approval of Vedolizumab

FDA Committee Recommends Approval of Takeda’s Investigational Biologic Vedolizumab, DEERFIELD, Ill. and OSAKA, Japan, Dec. 9, 2013 weneedideas.ca Takeda Pharmaceutical Company Limited (“Takeda”) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a joint panel of members from the Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees of the United States […]

Crohn’s Disease Drug Safety Review by FDA

Crohn’s Disease Drug Safety Review by FDA

Crohn’s Disease Drug Safety Review by FDA, WASHINGTON The investigational biologic vedolizumab being submitted for the treatment of Crohn’s disease and ulcerative colitis comes with safety concerns, FDA reviewers said. In a briefing document released Thursday in advance of Monday’s joint FDA advisory committee meeting to consider whether to recommend approval of the drug, reviewers […]

IBD Therapy Lasts Longer With Crohn’s

Patients with Crohn’s disease continued treatment with a TNF inhibitor significantly longer than did patients with ulcerative colitis, contradicting perceived similar activity in the two conditions, investigators reported here. The Crohn’s group treated with infliximab Remicade had a mean time to treatment failure exceeding 2 years (28.5 months), whereas failure occurred in 9.47 months among […]

Marketing Guide Ulcerative Colitis Study

Marketing Guide Ulcerative Colitis Study

Marketing Guide Ulcerative Colitis Study More than 40 percent of patients with moderate to severe ulcerative colitis achieved clinical remission from the debilitating condition after a year of taking an experimental drug developed by Japan’s Takeda Pharmaceutical Co, according to data from a pivotal late-stage trial. Read full Takeda drug impresses in ulcerative colitis study […]

Medications for Crohn’s Disease

Medications for Crohn’s Disease

Medications for Crohn’s Disease, Thanks to research and development there are several drugs that have been approved and are being used to help Crohn’s patients deal with the symptoms

Crohns Disease Medications

Infliximab (Remicade®): Crohn’s disease Medication Infliximab (Remicade®) is a medication for severe Crohn’s disease. It is used to treat Crohn’s disease in patients who have not been helped by other medicines and also in patients who have a type of Crohn’s disease in which fistulas form. Infliximab (Remicade®) is an immunosuppressive medication, which means that […]

Trial of Growth Hormone Therapy in Pediatric Crohn’s Disease

Trial of Growth Hormone Therapy in Pediatric Crohn’s Disease

Trial of Growth Hormone Therapy in Pediatric Crohn’s Disease This study has been completed.   First Received on April 28, 2005.   Last Updated on October 10, 2011   History of Changes Sponsor: Collaborator: Genentech Information provided by (Responsible Party): Children’s Hospital Medical Center, Cincinnati ClinicalTrials.gov Identifier: NCT00109473   Purpose The purpose of this study […]

No Guts Know Glory

IDEAS Kids

IDEAS Kids

IBD Adventures